Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis

Yukie Yamaguchi, Yuka Okazaki, Noriyuki Seta, Takashi Satoh, Kazuo Takahashi, Zenro Ikezawa, Masataka Kuwana

Research output: Contribution to journalArticle

22 Citations (Scopus)

Abstract

Introduction: Microvasculopathy is one of the characteristic features in patients with systemic sclerosis (SSc), but underlying mechanisms still remain uncertain. In this study, we evaluated the potential involvement of monocytic endothelial progenitor cells (EPCs) in pathogenic processes of SSc vasculopathy, by determining their number and contribution to blood vessel formation through angiogenesis and vasculogenesis.Methods: Monocytic EPCs were enriched and enumerated using a culture of peripheral blood mononuclear cells and platelets on fibronectin in 23 patients with SSc, 22 patients with rheumatoid arthritis (RA), and 21 healthy controls. To assess the capacity of monocytic EPCs to promote vascular formation and the contribution of vasculogenesis to this process, we used an in vitro co-culture system with human umbilical vein endothelial cells (HUVECs) on Matrigel® and an in vivo murine tumor neovascularization model.Results: Monocytic EPCs were significantly increased in SSc patients than in RA patients or healthy controls (P = 0.01 for both comparisons). Monocytic EPCs derived from SSc patients promoted tubular formation in Matrigel® cultures more than those from healthy controls (P = 0.007). Transplantation of monocytic EPCs into immunodeficient mice resulted in promotion of tumor growth and blood vessel formation, and these properties were more prominent in SSc than healthy monocytic EPCs (P = 0.03 for both comparisons). In contrast, incorporation of SSc monocytic EPCs into the tubular structure was less efficient in vitro and in vivo, compared with healthy monocytic EPCs.Conclusions: SSc patients have high numbers of aberrant circulating monocytic EPCs that exert enhanced angiogenesis but are impaired in vasculogenesis. However, these cells apparently cannot overcome the anti-angiogenic environment that characterizes SSc-affected tissues.

Original languageEnglish
Article numberR205
JournalArthritis Research and Therapy
Volume12
Issue number6
DOIs
Publication statusPublished - 2010 Nov 4

Fingerprint

Systemic Scleroderma
Blood Vessels
Rheumatoid Arthritis
Endothelial Progenitor Cells
Vascular Tissue Neoplasms
Human Umbilical Vein Endothelial Cells
Coculture Techniques
Fibronectins
Blood Cells
Blood Platelets
Transplantation

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Immunology and Allergy
  • Medicine(all)

Cite this

Yamaguchi, Y., Okazaki, Y., Seta, N., Satoh, T., Takahashi, K., Ikezawa, Z., & Kuwana, M. (2010). Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. Arthritis Research and Therapy, 12(6), [R205]. https://doi.org/10.1186/ar3180

Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. / Yamaguchi, Yukie; Okazaki, Yuka; Seta, Noriyuki; Satoh, Takashi; Takahashi, Kazuo; Ikezawa, Zenro; Kuwana, Masataka.

In: Arthritis Research and Therapy, Vol. 12, No. 6, R205, 04.11.2010.

Research output: Contribution to journalArticle

Yamaguchi, Y, Okazaki, Y, Seta, N, Satoh, T, Takahashi, K, Ikezawa, Z & Kuwana, M 2010, 'Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis', Arthritis Research and Therapy, vol. 12, no. 6, R205. https://doi.org/10.1186/ar3180
Yamaguchi, Yukie ; Okazaki, Yuka ; Seta, Noriyuki ; Satoh, Takashi ; Takahashi, Kazuo ; Ikezawa, Zenro ; Kuwana, Masataka. / Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis. In: Arthritis Research and Therapy. 2010 ; Vol. 12, No. 6.
@article{5dbe66f6a85c4479979953f75ff8901b,
title = "Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis",
abstract = "Introduction: Microvasculopathy is one of the characteristic features in patients with systemic sclerosis (SSc), but underlying mechanisms still remain uncertain. In this study, we evaluated the potential involvement of monocytic endothelial progenitor cells (EPCs) in pathogenic processes of SSc vasculopathy, by determining their number and contribution to blood vessel formation through angiogenesis and vasculogenesis.Methods: Monocytic EPCs were enriched and enumerated using a culture of peripheral blood mononuclear cells and platelets on fibronectin in 23 patients with SSc, 22 patients with rheumatoid arthritis (RA), and 21 healthy controls. To assess the capacity of monocytic EPCs to promote vascular formation and the contribution of vasculogenesis to this process, we used an in vitro co-culture system with human umbilical vein endothelial cells (HUVECs) on Matrigel{\circledR} and an in vivo murine tumor neovascularization model.Results: Monocytic EPCs were significantly increased in SSc patients than in RA patients or healthy controls (P = 0.01 for both comparisons). Monocytic EPCs derived from SSc patients promoted tubular formation in Matrigel{\circledR} cultures more than those from healthy controls (P = 0.007). Transplantation of monocytic EPCs into immunodeficient mice resulted in promotion of tumor growth and blood vessel formation, and these properties were more prominent in SSc than healthy monocytic EPCs (P = 0.03 for both comparisons). In contrast, incorporation of SSc monocytic EPCs into the tubular structure was less efficient in vitro and in vivo, compared with healthy monocytic EPCs.Conclusions: SSc patients have high numbers of aberrant circulating monocytic EPCs that exert enhanced angiogenesis but are impaired in vasculogenesis. However, these cells apparently cannot overcome the anti-angiogenic environment that characterizes SSc-affected tissues.",
author = "Yukie Yamaguchi and Yuka Okazaki and Noriyuki Seta and Takashi Satoh and Kazuo Takahashi and Zenro Ikezawa and Masataka Kuwana",
year = "2010",
month = "11",
day = "4",
doi = "10.1186/ar3180",
language = "English",
volume = "12",
journal = "Arthritis Research and Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "6",

}

TY - JOUR

T1 - Enhanced angiogenic potency of monocytic endothelial progenitor cells in patients with systemic sclerosis

AU - Yamaguchi, Yukie

AU - Okazaki, Yuka

AU - Seta, Noriyuki

AU - Satoh, Takashi

AU - Takahashi, Kazuo

AU - Ikezawa, Zenro

AU - Kuwana, Masataka

PY - 2010/11/4

Y1 - 2010/11/4

N2 - Introduction: Microvasculopathy is one of the characteristic features in patients with systemic sclerosis (SSc), but underlying mechanisms still remain uncertain. In this study, we evaluated the potential involvement of monocytic endothelial progenitor cells (EPCs) in pathogenic processes of SSc vasculopathy, by determining their number and contribution to blood vessel formation through angiogenesis and vasculogenesis.Methods: Monocytic EPCs were enriched and enumerated using a culture of peripheral blood mononuclear cells and platelets on fibronectin in 23 patients with SSc, 22 patients with rheumatoid arthritis (RA), and 21 healthy controls. To assess the capacity of monocytic EPCs to promote vascular formation and the contribution of vasculogenesis to this process, we used an in vitro co-culture system with human umbilical vein endothelial cells (HUVECs) on Matrigel® and an in vivo murine tumor neovascularization model.Results: Monocytic EPCs were significantly increased in SSc patients than in RA patients or healthy controls (P = 0.01 for both comparisons). Monocytic EPCs derived from SSc patients promoted tubular formation in Matrigel® cultures more than those from healthy controls (P = 0.007). Transplantation of monocytic EPCs into immunodeficient mice resulted in promotion of tumor growth and blood vessel formation, and these properties were more prominent in SSc than healthy monocytic EPCs (P = 0.03 for both comparisons). In contrast, incorporation of SSc monocytic EPCs into the tubular structure was less efficient in vitro and in vivo, compared with healthy monocytic EPCs.Conclusions: SSc patients have high numbers of aberrant circulating monocytic EPCs that exert enhanced angiogenesis but are impaired in vasculogenesis. However, these cells apparently cannot overcome the anti-angiogenic environment that characterizes SSc-affected tissues.

AB - Introduction: Microvasculopathy is one of the characteristic features in patients with systemic sclerosis (SSc), but underlying mechanisms still remain uncertain. In this study, we evaluated the potential involvement of monocytic endothelial progenitor cells (EPCs) in pathogenic processes of SSc vasculopathy, by determining their number and contribution to blood vessel formation through angiogenesis and vasculogenesis.Methods: Monocytic EPCs were enriched and enumerated using a culture of peripheral blood mononuclear cells and platelets on fibronectin in 23 patients with SSc, 22 patients with rheumatoid arthritis (RA), and 21 healthy controls. To assess the capacity of monocytic EPCs to promote vascular formation and the contribution of vasculogenesis to this process, we used an in vitro co-culture system with human umbilical vein endothelial cells (HUVECs) on Matrigel® and an in vivo murine tumor neovascularization model.Results: Monocytic EPCs were significantly increased in SSc patients than in RA patients or healthy controls (P = 0.01 for both comparisons). Monocytic EPCs derived from SSc patients promoted tubular formation in Matrigel® cultures more than those from healthy controls (P = 0.007). Transplantation of monocytic EPCs into immunodeficient mice resulted in promotion of tumor growth and blood vessel formation, and these properties were more prominent in SSc than healthy monocytic EPCs (P = 0.03 for both comparisons). In contrast, incorporation of SSc monocytic EPCs into the tubular structure was less efficient in vitro and in vivo, compared with healthy monocytic EPCs.Conclusions: SSc patients have high numbers of aberrant circulating monocytic EPCs that exert enhanced angiogenesis but are impaired in vasculogenesis. However, these cells apparently cannot overcome the anti-angiogenic environment that characterizes SSc-affected tissues.

UR - http://www.scopus.com/inward/record.url?scp=78049367109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78049367109&partnerID=8YFLogxK

U2 - 10.1186/ar3180

DO - 10.1186/ar3180

M3 - Article

C2 - 21050433

AN - SCOPUS:78049367109

VL - 12

JO - Arthritis Research and Therapy

JF - Arthritis Research and Therapy

SN - 1478-6354

IS - 6

M1 - R205

ER -